弥漫性皮肤型系统性硬化症皮肤纤维化进展与肺功能下降及生存恶化相关
基于EUSTAR队列1021例弥漫性皮肤型系统性硬化症(dcSSc)患者,评估1年内皮肤纤维化进展与内脏进展及死亡的关系。皮肤进展者(78例,7.6%)FVC下降≥10%概率(53.6% vs 34.4%)和全因死亡概率(15.4% vs 7.3%)显著更高;多变量分析显示皮肤进展独立关联FVC下降≥10%(HR 1.79)和全因死亡(HR 2.58)。
要点
- 1年内mRSS增加>5且≥25%定义为皮肤纤维化进展,与FVC下降≥10%独立相关。
- 皮肤进展者全因死亡风险是非进展者的2.58倍(95%CI 1.31-5.09)。
- 低基线mRSS(≤22/51)或短病程(≤15个月)亚组中上述关联仍显著。
核心结论
- dcSSc患者1年内皮肤纤维化进展与肺功能下降及全因死亡风险升高独立相关。
- mRSS可作为dcSSc的替代标志物,有助于未来试验队列富集和临床风险分层。
研究设计与样本
- 基于欧洲硬皮病试验与研究(EUSTAR)数据库的多中心队列研究。
- 纳入1021例dcSSc患者,基线mRSS≥7,且基线后12±3个月mRSS有效并至少1次年度随访。
- 皮肤进展定义为基线至12±3个月mRSS增加>5且≥25%。
- 采用Kaplan-Meier生存分析和多变量Cox回归评估关联。
主要发现
- 78例(7.6%)为皮肤进展者,中位随访3.4年。
- 皮肤进展者FVC下降≥10%概率显著高于非进展者(53.6% vs 34.4%;p<0.001)。
- 皮肤进展者全因死亡概率显著高于非进展者(15.4% vs 7.3%;p=0.003)。
- 多变量分析中,1年内皮肤进展独立关联FVC下降≥10%(HR 1.79,95%CI 1.20-2.65)。
- 多变量分析中,1年内皮肤进展独立关联全因死亡(HR 2.58,95%CI 1.31-5.09)。
关键数值与推荐
- 皮肤进展定义:基线至12±3个月mRSS增加>5且≥25%。
- 纳入标准:dcSSc,基线mRSS≥7,基线后12±3个月mRSS有效,至少1次年度随访。
- 亚组分析:低基线mRSS(≤22/51)或短病程(≤15个月)患者中关联仍显著。
临床怎么用
- 对dcSSc患者应定期评估mRSS,1年内皮肤纤维化进展提示肺功能下降和死亡风险升高。
- mRSS进展可用于临床风险分层,辅助识别需密切监测肺功能和强化管理的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine whether progressive skin fibrosis is associated with visceral organ progression and mortality during follow-up in patients with diffuse cutaneous systemic sclerosis (dcSSc). METHODS: We evaluated patients from the European Scleroderma Trials and Research database with dcSSc, baseline modified Rodnan skin score (mRSS) ≥7, valid mRSS at 12±3 months after baseline and ≥1 annual follow-up visit. Progressive skin fibrosis was defined as an increase in mRSS >5 and ≥25% from baseline to 12±3 months. Outcomes were pulmonary, cardiovascular and renal progression, and all-cause death. Associations between skin progression and outcomes were evaluated by Kaplan-Meier survival analysis and multivariable Cox regression. RESULTS: Of 1021 included patients, 78 (7.6%) had progressive skin fibrosis (skin progressors). Median follow-up was 3.4 years. Survival analyses indicated that skin progressors had a significantly higher probability of FVC decline ≥10% (53.6% vs 34.4%; p<0.001) and all-cause death (15.4% vs 7.3%; p=0.003) than non-progressors. These significant associations were also found in subgroup analyses of patients with either low baseline mRSS (≤22/51) or short disease duration (≤15 months). In multivariable analyses, skin progression within 1 year was independently associated with FVC decline ≥10% (HR 1.79, 95% CI 1.20 to 2.65) and all-cause death (HR 2.58, 95% CI 1.31 to 5.09). CONCLUSIONS: Progressive skin fibrosis within 1 year is associated with decline in lung function and worse survival in dcSSc during follow-up. These results confirm mRSS as a surrogate marker in dcSSc, which will be helpful for cohort enrichment in future trials and risk stratification in clinical practice.
引用
- Wu W, Jordan S, Graf N, et al. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann Rheum Dis. 2019. PMID: 30852552. doi:10.1136/annrheumdis-2018-213455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。